Cardiovascular　disease　remains　the　dominant　contributor　to　human　mortality,　and　the　main　etiology　of　which　is　atherosclerosis　(AS).　Enhancing　the　targeted　ability　of　nanosystem　and　improving　plaque　stability　are　critical　challenges　for　the　current　management　of　AS.　Herein,　we　leverage　the　marked　role　of　platelets　in　AS　to　construct　a　biomimetic　nanodrug　delivery　system　(PM@Se/Rb1　NPs),　which　prepared　by　cloaking　platelet　membrane　(PM)　around　Selenium　(Se)　and　ginsenoside　Rb1　nanoparticles　(Se/Rb1　NPs)　core.　The　core　endows　the　delivery　system　antioxidant,　lipid　metabolism　and　anti-inflammatory　effects　for　AS　effective　treatment.　Moreover,　PM　coated　nanoparticles　reserve　platelets＇　inherent　biological　elements　to　deliver　drugs　to　plaques.　We　further　explored　the　potential　effect　of　PM@Se/Rb1　NPs＇　combination　with　the　clinical　anticoagulant　drug　warfarin　(War)　to　treat　AS　and　elucidated　the　possible　drug　interaction　mechanism.　As　a　result,　the　PM@Se/Rb1　NPs　are　not　only　capable　of　improving　inflammatory　behaviors　such　as　inhibitory　adhesion　ability　and　anti-angiogenesis　therapeutic　effect　in　vitro,　but　also　administer　efficiently　localizing　to　atherosclerotic　plaque　explaining　by　aortic　samples　from　established　ApoE(-/-&　nbsp;)mice.　Therefore,　this　study　provided　a　theoretical　basis　of　biomimetic　nanodrug　in　the　treatment　of　AS　as　well　as　an　effective　reference　for　the　combined　application　of　nanodrug　and　clinical　drugs.